Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

BRIEF-Mithra Pharmaceuticals Signs Agreement With Mayne Pharma

Published 28/05/2020, 04:27 pm
© Reuters.
MITRA
-

May 28 (Reuters) - MITHRA PHARMACEUTICALS SA MITRA.BR :

* MITHRA SIGNS LICENSE AND SUPPLY AGREEMENT WITH MAYNE PHARMA FOR COMMERCIALIZATION OF ESTELLE IN AUSTRALIA

* MITHRA ELIGIBLE FOR MILESTONE AND LICENSE FEES OF UP TO EUR 3.5 MILLION

* PREPARATION ONGOING FOR COMMERCIAL LAUNCH OF MITHRA'S ORAL CONTRACEPTIVE IN U.S. AND AUSTRALIA, TARGETED FOR H1 AND H2 2021 RESPECTIVELY

* CONSOLIDATION OF PARTNERSHIP WITH MAYNE PHARMA FOR COMMERCIALIZATION OF THE COMBINED ORAL CONTRACEPTIVE E4/DRSP (ESTELLE®1) IN AUSTRALIA

* PRODUCT IS EXPECTED TO BE FILED WITH AUSTRALIAN AGENCY TGA IN 2020 AND LAUNCHED IN SECOND HALF OF CALENDAR 2021

* WILL ALSO RECEIVE GUARANTEED ANNUAL RECURRING REVENUES BASED ON MINIMUM ANNUAL QUANTITIES IN ADDITION TO OTHER REVENUES ON NET SALES

* ON APPROVAL, PRODUCT IS EXPECTED TO RECEIVE FIVE YEARS OF DATA EXCLUSIVITY FROM TGA AS IT IS A NEW CHEMICAL ENTITY

* MAYNE HAS OPTION TO OBTAIN A LICENSE TO REGISTER AND LAUNCH PRODUCT IN NEW ZEALAND

* BASED ON MARKET ASSUMPTIONS AND MITHRA'S FORECAST, AGREEMENT REPRESENTS DEAL WORTH UP TO EUR 40 MILLION OVER PERIOD

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.